Last updated: February 23, 2026
What is NDC 51862-0074?
NDC 51862-0074 identifies a specific drug product registered in the United States. Based on available data, this NDC corresponds to Blenrep (belantamab mafodotin-blmf), a targeted therapy approved by the FDA for relapsed or refractory multiple myeloma.
Market Context
Approved Indications and Current Usage
Blenrep received FDA approval in August 2020 under NDA 761144, primarily for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.[1] Its targeted mechanism involves antibody-drug conjugates (ADCs), a niche within oncology treatments.
Market Size
The total addressable market for multiple myeloma therapies in the U.S. was valued at approximately $6.4 billion in 2022, driven by increasing diagnosis rates and shifts toward novel agents.[2] The relapsed/refractory segment accounts for nearly 40% of this market, with an expected compound annual growth rate (CAGR) of 6% through 2030.
Specific to belantamab mafodotin, sales projections suggest reaching approximately $300 million domestically by 2025, considering the initial adoption rate, expanded indications, and market penetration.
Competition Landscape
Blenrep faces competition from other approved agents:
- Carfilzomib (Kyprolis)
- Ixazomib (Ninlaro)
- Daratumumab (Darzalex)
- Elotuzumab (Empliciti)
- Newer agents, such as idecabtagene vicleucel (CAR-T therapy), are emerging as more aggressive options.
Market share will depend on efficacy outcomes, safety profiles, and reimbursement pathways, with Blenrep positioned as an option for heavily pretreated patients.
Price Projections
Current Pricing
The wholesale acquisition cost (WAC) for Blenrep in 2023 maintains around $11,200 per dose. The typical dosing schedule involves 2.5 mg/kg administered intravenously once every three weeks. The average patient weight for calculations is approximately 70 kg, equating to a per-dose cost of about $175,000 annually assuming a full year of treatment.
Payor and Reimbursement Trends
- The average net price after discounts and rebates is approximately $188,000 per year based on market data.[3]
- Reimbursement strategies and insurance coverage significantly impact the net selling price and patient access.
Price Trends and Future Projections
Three primary factors influence future pricing:
-
Market Competition and Patent Life
Market entry of biosimilars or novel agents could pressure prices downward, especially post patent expiry, anticipated around 2030.
-
Regulatory Changes
Pricing reforms or value-based payment models may promote price concessions, aligning reimbursement with clinical benefits.
-
Expansion into New Indications
If Blenrep gains approval for earlier lines of therapy or combinations, pricing could adjust upwards due to higher volume and perceived value.
Based on comparable ADC therapies, a conservative scenario suggests:
| Year |
Price per Dose |
Notes |
| 2023 |
$11,200 |
Current list price |
| 2025 |
$10,500 |
Slight decline due to market pressure |
| 2030 |
$9,500 |
Potential decline if biosimilars introduced |
Total annual sales could range from $250 million to $400 million over the next five years, considering market expansion and pricing trends.
Key Drivers and Risks
- Market penetration depends on physician acceptance, device of administration, and safety profile.
- Safety concerns from ocular toxicity reports may limit use or influence pricing negotiations.
- Regulatory developments can alter market exclusivity and competition, impacting prices.
Summary
Blenrep (NDC 51862-0074) operates within a growing, competitive oncology market, with current U.S. pricing around $188,000 annually. Price projections indicate modest declines over the next five years amid an expanding treatment landscape and emerging competitors. The market size for relapsed/refractory multiple myeloma therapies underpins a multi-billion-dollar industry, with Blenrep securing a niche that may see modest growth if it secures additional indications.
Key Takeaways
- Blenrep’s 2023 list price is approximately $188,000 annually.
- Market forecasts predict slight price declines by 2030, influenced by biosimilar competition and value-based pricing.
- The total market for relapsed/refractory multiple myeloma therapy approaches $2.6 billion in the U.S.
- Sales depend heavily on approval for broader indications and physician adoption.
- Pricing strategies will likely need adjustments to remain competitive as biosimilars and novel therapies gain market share.
FAQs
Q1: When is patent expiry expected for Blenrep?
Patent protection generally extends to approximately 12 years from approval, estimating around 2032, depending on patent filings and legal challenges.
Q2: What are the main competitors to Blenrep?
Carfilzomib, ixazomib, and daratumumab are primary competitors, with emerging CAR-T therapies.
Q3: How do safety concerns impact pricing?
Ocular toxicity may lead to increased monitoring costs and safety-related label updates, potentially reducing the drug’s market appeal and pricing power.
Q4: What is the outlook for biosimilars?
Biosimilar versions of ADCs could appear post-2030, driving prices downward significantly.
Q5: Are there plans for expanding indication?
Pending clinical trial results, extension into earlier lines of multiple myeloma treatment could increase sales volume and justify higher pricing or value-based agreements.
References
[1] FDA. (2020). FDA approves Blenrep for relapsed or refractory multiple myeloma.
[2] IQVIA. (2022). U.S. oncology market report.
[3] SSR Health. (2023). 2022 US Brand Drug Market Data.
